Interaction of Dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system

European Journal of Pharmacology

Volumn 338, Issue 3, 1997, Pages 205-213

  Striem, Sarina ^a   Bar Joseph, Avi ^a   Berkovitch, Yafit ^a   Biegon, Anat ^a  

^a PHARMOS LTD   (Israel)

Author keywords

Catalepsy; Dopamine receptor antagonist; HU 211; NMDA receptor antagonist; Parkinson's disease'

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; CLEBOPRIDE; CYCLIC AMP; DEXANABINOL; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CATALEPSY; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FOREBRAIN; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030701496     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)81923-1     Document Type: Article

References (41)

1. Baldwin H.A., Colado M.I., Murray T.K., De Souza R.J., Green A.R. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br. J. Pharmacol. 108:1993;590.
2. Bar-Joseph A., Berkovitch Y., Adamchik J., Biegon A. Neuroprotective activity of HU-211, a novel NMDA receptor antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol. 23:1994;125.
3. Bar-Joseph A., Berkovich Y., Belayev L., Adamchik J., Biegon A. Neuroprotective activity of HU-211: Dose response and therapeutic window. Abstr. Soc. Neurosci. 82:1994;11.
4. Bar-Joseph A., Berkovich Y., Belayev L., Adamchik J., Biegon A. Behavioral and physiological profile of HU-211, a novel non-competitive NMDA receptor antagonist. J. Cereb. Blood Flow Metab. 15 (Suppl. 1):1995;S429.
5. Belayev L., Bar-Joseph A., Adamchik J., Biegon A. HU-211, a nonpsychotrophic cannabinoid, improves neurologic signs and reduces brain damage after severe forebrain ischemia in rats. Mol. Chem. Neuropathol. 25:1995;19.
6. Belayev L., Busto R., Watson B.D., Ginsberg M.D. Post-ischemic administration of HU-211, a novel non-competitive antagonist, protects against blood-brain barrier disruption in photochemical cortical infraction in rats; A quantitative study. Brain Res. 702:1995;266.
7. Belayev L., Busto R., Zhao E., Ginsberg M.D. HU-211, a novel N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke. 26:1995;2313.
8. Biegon A., Bar-Joseph A. Development of HU-211 as a neuroprotectant for ischemic brain damage. Neurol. Res. 17:1995;275.
9. Carlsson M., Carlsson A. Interactions between glutaminergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends Neurol. Sci. 13:1990;272.
10. Deary A., Gingrich J.A., Falardeau P., Fremeau J.R., Bates M.D., Aron M.G. Molecular cloning and expression of the gene for a human dopamine D1 receptor. Nature. 347:1990;72.
11. Devane W.A., Dysarz M.R.J., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605.
12. Devane W.A., Breuer A., Sheskin T., Jarbe T.U.C., Eisen M.S., Mechoulam R. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:1992;2065.
13. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurol. Sci. 17:1994;228.
14. Eshhar N., Gerardo L.K., Beaujean M., Goldberg O., Gregor P., Triller A., Teichberg V.I. Kainyl-bovine serum albumin: A novel ligand of the kainate subtype of glutamate receptor with a very high binding affinity. Brain Res. 476:1989;57.
15. Eshhar N., Striem S., Biegon A. HU-211, a nonpsychotropic cannabinoid, rescues cortical neurons from excitatory amino acid toxicity in culture. NeuroReport. 5:1993;237.
16. Eshhar N., Striem S., Kohen R., Tirosh O., Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 283:1995;19.
17. Feigenbaum J.J., Bergman F., Richmond S.A., Mechoulam R., Nadler V., Kloog Y., Sokolovsky M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. 89:1989;9584.
18. 2 dopamine receptor function in rat striatum. Pharmacol. Biochem. Behav. 44:1992;683.
19. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgesics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol. Pharmacol. 33:1988;297.
20. Howlett A.C., Champion T.M., Wilken G.H., Mechoulam R. Stereochemical effects of 11-OH-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 29:1990;161.
21. Iversen L.L. Dopamine receptors in the brain. Science. 188:1975;1084.
22. Klockgether T., Turski L. NMDA receptor antagonists potentiate anti-Parkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28:1990;539.
23. Koek W., Woods J.H., Colparet F.C. NMDA antagonism and phencyclidine-like activity. A drug discrimination analysis. J. Pharmacol. Exp. Ther. 253:1990;1017.
24. Leander J.D., Lawson R.R., Ornstein P.L., Zimmerman D.H. NMDA-induced lethality in mice: Selective antagonism by phenylclidine-like drugs. Brain Res. 498:1988;115.
25. Löscher W., Honack D. Anti-convulsant and behavioral effects of two novel competitive NMDA receptor antagonists, CGP 37849 and cgp 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 256:1990;432.
26. Löscher W., Annies R., Hönack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191.
27. Meldrum B., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative diseases. Trends Pharmacol. Sci. 11:1990;379.
28. 2 receptor antagonists. Eur. J. Pharmacol. 237:1993;1.
29. 2-mediated behavior in the 6-hydroxydopamine model of turning: Relationship to c-fos expression. J. Pharmacol. Exp. Ther. 260:1993;402.
30. Nadler V., Mechoulam R., Sokolovsky M. The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ-6 tetrahydro-cannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci. Lett. 162:1993;43.
31. 2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211 Brain Res. 622:1993;79.
32. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurol. Sci. 16:1993;439.
33. 3H]cAMP in cell monolayers, cell suspensions and tissue slices. Methods Enzymol. 195:1991;22.
34. Shohami E., Novikov M., Mechoulam R. A non-psychotropic cannabinoid, HU-211, has cerebro-protective effects after closed-head injury in the rat. J. Neurotrauma. 10:1993;109.
35. Shohami E., Novikov M., Bass R. Long term effect of HU-211, a novel non-competitive NMDA receptor antagonist, in motor and memory functions after closed head injury in the rat. Brain Res. 674:1995;55.
36. 2, mediated changes in striatal and accumbens neurotensin systems. Brain Res. 571:1992;260.
37. Sonsalla P.K., Nicklas W.J., Heikkila R.E. Role of excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:1989;398.
38. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease/Alzheimer's disease patients: An autoradiographic study. J. Neurosci. 14:1994;6317.
39. Van Calker D., Muller M., Hamprecht B. Adrenergic α- and β-receptors expressed by the same cell type in primary culture of perinatal mouse brain. J. Neurochem. 30:1978;713.
40. Weihmuller F.B., Ulas J., Nguyen L., Cotman C.W., Marshall J.F. Elevated NMDA receptors in Parkinsonian striatum. Neuroreport. 3:1992;977.
41. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - A possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136.